Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis

Overview of attention for article published in PLOS ONE, July 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

patent: 4 patents

Citations

dimensions_citation: 75 Dimensions

Readers on

mendeley: 110 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

ANTI-HUMAN CCR1 MONOCLONAL ANTIBODY

Application WO-2019017401-A1

World Intellectual Property Organisation (WIPO)

Antigen binding proteins that bind CCR2

Application US-9951138-B2

United States of America

ANTI-HUMAN CCR1 MONOCLONAL ANTIBODY

Application WO-2017126587-A1

World Intellectual Property Organisation (WIPO)

Antigen binding proteins that bind CCR2

Grant US-9315579-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.